item management s discussion and analysis of financial condition and results of operation results of operations years ended december   and revenues 
total revenues decreased by  or during as compared to and increased by  or between and the increase between and was primarily a result of revenue recognized pursuant to a collaborative agreement with abbott laboratories abbott relating to the actiq cancer pain program see note to financial statements 
substantially all revenues in all years were from development funding and milestone payments under collaborative agreements with abbott relating to the actiq cancer pain program 
amounts earned under the collaborative agreements with abbott may vary substantially in the future 
under the company s agreement with abbott  abbott manufactures fentanyl oralet and sells it to the company at a price which reflects abbott s cost of manufacturing 
the company then sells the product to abbott at a price related to abbott s selling price which results in a gross profit to the company ranging from approximately 
in addition  the company is entitled to receive a royalty on product sales by abbott 
operating expenses 
research and development expenses increased by  or during as compared to and by  or between and the increase in research and development expenses in and was due primarily to higher expenditures for the actiq cancer pain program see note to financial statements  new product development and other expenditures for product development  including clinical trials 
the company expects that its research and development expenses will grow significantly during as a result of increased expenses related to the hiring of additional personnel  preclinical studies  clinical trials  product development and process development activities 
depreciation expense increased by  or during as compared to and by  or between and the increase in is primarily due to a decrease in the estimated useful life of specific leasehold improvements and the increase in is primarily due to the company s remodeling of new facilities 
marketing  general and administrative expenses increased by  or during as compared to and by  or between and the increase in was due primarily to higher expenditures for corporate development activities  marketing research  actiq pre marketing activities  rent on new facilities  patent activities and equipment leasing 
the increase in was due primarily to higher expenditures resulting from additional executives and employees  increased support required for research and development  patent and corporate development activities 
the company expects that its marketing  general and administrative expenses will increase significantly during as a result of the increased support required for research and development  marketing research  actiq pre launch market development activities  patent and corporate development activities 
non operating income expense 
interest income increased by  during as compared to and by  between and the increase in is primarily due to invested net proceeds of  from the company s secondary offering in june the increase in is primarily due to higher interest rates  partially offset by lower average balances invested 
interest expense increased by  during as compared to and by  between and the increase in both years is primarily due to interest expense related to borrowings on the company s revolving term loan 
income taxes 
as of december   the company had net operating loss carryforwards of approximately million and research and development tax credit carryforwards of  that expire from to a portion of the company s net operating loss and research and development tax credit carryforwards are subject to an annual limitation in future periods pursuant to the change in ownership rules under section of the internal revenue code of  as amended 
based upon the amount of carryforwards subject to limitation  the date the limitation arose  and the estimated value of the company on the change of ownership date  the company believes that the limitation will not have a material impact on the future use of net operating loss and research and development tax credit carryforwards 
the company s ability to realize the benefit of the deferred tax asset related to the net operating loss and research and development tax credit carryforwards will depend on the generation of future taxable income 
because the company s operations are not currently generating taxable income  the company believes a full valuation allowance should be provided see note to financial statements 
accounting change 
effective january   the company changed its method of accounting for external legal costs related to patents 
prior to the change  the company capitalized these costs and amortized them over the term of the related patent 
under the new method  these costs are expensed as incurred 
net loss 
as a result of the increase in research and development  marketing  general and administrative activities and other factors discussed above  the net loss for was  or per share as compared to  or per share for and  or per share in the net loss for includes the cumulative effect of a change in accounting for patent costs of  or per share 
liquidity and capital resources prior to january  the company had funded its operations primarily through private equity financings and through contract payments pursuant to the company s agreements with abbott 
in february  the company realized net proceeds of  through the issuance of common stock in an initial public offering and approximately  from the exercise of warrants held by abbott 
in conjunction with the conversion of preferred stock  a one time payment of accrued dividends of  was made in february in june the company realized net proceeds of  through the issuance of common stock in a secondary offering 
as of december   the company had cash and cash equivalents totaling   in a certificate of deposit used as collateral for a revolving term loan as described below and  in marketable debt securities which are available for sale 
thus cash  cash equivalents  certificate of deposit and marketable debt securities totaled  as of december  cash in excess of immediate requirements is invested according to the company s investment policy  which provides guidelines with regard to liquidity and return  and  wherever possible  seeks to minimize the potential effects of concentration of credit risk 
the company s use of cash in operating activities increased by  during as compared to and by  between and the increase in cash used was a direct result of the increase in research and development and marketing  general and administrative activities discussed above 
during  the company made capital expenditures of approximately  as compared to capital expenditures of  and  in and respectively 
the increase in capital expenditures in was due to the company s remodeling of new facilities 
in order to finance the capital expenditures  the company  in january  secured a revolving term loan in the amount of  which is collateralized by a  certificate of deposit purchased in this loan converted to a year term loan on may during the company paid  on capital lease obligations as compared to  and  in and respectively 
the company expects to continue to incur substantial expenses related to the continuation and expansion of research and development  including clinical trials  and increased marketing  general and administrative activities over at least the next several years 
the company anticipates that the existing cash  cash equivalents and marketable debt securities  and interest earned thereon provides adequate working capital through the company s working capital requirements may change depending on numerous factors  including the following  the progress of the company s research and development programs  the results of clinical studies  the number and nature of the indications the company pursues in clinical studies  the timing of regulatory approvals  technological advances  determinations as to the commercial potential of the company s products  the status of competitive products  the establishment of collaborative relationships with other companies and other factors 
in june  the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 accounting for transfers and servicing of financial assets and extinguishments of liabilities 
sfas no 
becomes effective at the beginning of the company does not believe that sfas no 
will have a significant impact on the financial statements of the company 
in february  the fasb issued sfas no 
 earnings per share which specifies the computation  presentation  and disclosure requirements for earnings per share 
the company will have to implement sfas no 
in the fourth quarter of the impact of the adoption of sfas no 
on the company s financial statements has not been determined 

